JN-210

JN-210 is an investigational gene therapy drug developed for the treatment of hypertrophic cardiomyopathy, specifically familial hypertrophic cardiomyopathy. It is designed as a viral vector that delivers an activator of microRNA miR-133, aiming to modulate cardiac muscle growth and function. The mechanism involves upregulation (activation) of miR-133, which plays a key role in cardiac muscle biology and has been implicated in the pathogenesis of hypertrophic cardiomyopathy. By activating miR-133, JN-210 seeks to counteract pathological cardiac remodeling associated with this disease. The drug is being developed by Jaan Biotherapeutics and has reached early Phase 1 clinical trials in the United States[1][2][4].